about
A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis CThe role of gender on clearance of hepatitis C virus: a different story in an area endemic for hepatitis B and CIdentification of groups with poor cost-effectiveness of peginterferon plus ribavirin for naïve hepatitis C patients with a real-world cohort and database.Peginterferon alfa-2a is associated with elevations in alanine aminotransferase at the end of treatment in chronic hepatitis C patients with sustained virologic responseTranslational research of telecare for the treatment of hepatitis C.Meta-analysis: superior treatment response in Asian patients with hepatitis C virus genotype 6 versus genotype 1 with pegylated interferon and ribavirinSexual Dimorphic Metabolic Alterations in Hepatitis C Virus-infected Patients: A Community-Based Study in a Hepatitis B/Hepatitis C Virus Hyperendemic Area.Inhibition of HCV 5'-NTR and core expression by a small hairpin RNA delivered by a histone gene carrier, HPhA.Host factors determining the efficacy of hepatitis C treatment.Systematic review: Asian patients with chronic hepatitis C infection.Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries.The safety and efficacy of peginterferon plus ribavirin in hepatitis C patients concomitant with malignancy other than hepatocellular carcinoma: a multicenter study.The tertiary prevention of hepatocellular carcinoma in chronic hepatitis C patients.Treatment efficacy of pegylated interferon plus ribavirin therapy in chronic hepatitis C patients with mixed genotype 1/2 infection.Performance characteristics of a real-time RT-PCR assay for quantification of hepatitis C virus RNA in patients with genotype 1 and 2 infections.A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan.Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link?Pegylated interferon plus ribavirin therapy improves pancreatic β-cell function in chronic hepatitis C patients.Acute appendicitis in patients with end-stage renal disease.Thyroid autoantibodies and dysfunction do not impact the treatment efficacy of peginterferon and ribavirin combination therapy in chronic hepatitis C.Hepatitis C virus infection causes hypolipidemia regardless of hepatic damage or nutritional state: An epidemiological survey of a large Japanese cohort.The emerging importance of chronic hepatitis C infection in Asian Americans.Cost-utility analysis of different peg-interferon alpha-2b plus ribavirin treatment strategies as initial therapy for naïve Chinese patients with chronic hepatitis C.Occurrence of diffuse, poorly differentiated hepatocellular carcinoma during pegylated interferon plus ribavirin combination therapy for chronic hepatitis C.Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C.Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C.The outcomes of glucose abnormalities in pre-diabetic chronic hepatitis C patients receiving peginterferon plus ribavirin therapy.The IL-6/STAT3 pathway upregulates microRNA-125b expression in hepatitis C virus infection.Hepatic Akt expression correlates with advanced fibrosis in patients with chronic hepatitis C infection.Hepatitis C Viremia Increases the Association With Type 2 Diabetes Mellitus in a Hepatitis B and C Endemic Area: An Epidemiological Link With Virological Implication
P2860
Q27478337-A3571B1B-CA27-4575-9886-08DB11182C60Q27480976-7B5FC5F3-0332-4B71-B627-BA3B6BBF4814Q33765497-B5783A22-847E-43A7-9146-87295AF7DDD6Q33769085-030B9EFA-5DF0-48D1-A38C-718041166879Q33809691-9B491A14-BB88-4420-9415-754318A5925CQ35153869-8905894F-22EC-4BA6-8981-C96808CC01E5Q36891841-82462579-6BC6-4815-A2CE-2D90230F2126Q36953104-CEB53F2F-FE17-444B-A544-E297605BA47EQ38056077-F9E56E31-2E41-4145-AB95-D0FE0E2A8EBCQ38096012-C5568605-1BB2-429B-8C58-E837B31FF294Q38459012-DBFC7997-535E-40E2-8610-956C95271298Q40707621-EDEBCADF-1CE7-4BD6-8BFD-E3DB8B204420Q41654105-0567CCA6-708C-4512-A1D2-13F45161FD20Q42249972-08375B2D-7248-408E-9148-8B520BFDB9B5Q42979735-AB79E699-08CB-4450-A880-024CD9E99581Q42997693-8115C6D3-4247-4445-AF40-FB00C2008F7AQ43030689-608A0318-801E-47C6-9DAD-C09CA4D9E074Q43038496-265345C8-5175-4C72-A021-943BBE9BB337Q43514719-32A05026-937E-482D-B4EF-0D2F8806270AQ43520862-96C70A9C-8A93-4BDC-AD78-73D990F82B6BQ44101703-D7E3E937-F592-4667-9C00-6C4787FE4238Q44600956-C2DEC876-3CF8-48EF-B799-95057E60B09AQ44604208-EAF2CD1C-ECE5-4CC5-8035-5CAB1E84CF93Q46497498-7DD80F35-78F3-4DFB-9148-8EF776A6CC24Q46866205-807848C7-6F58-4453-BFFB-D35430322276Q50550604-B6DA0E0A-3FCD-41F5-9F6C-B325A694773FQ50553281-1F8D495E-8D5B-45F9-8054-0B10199E9F41Q52655043-EA1F5058-8800-4C14-BEE7-54FA07B0CB2EQ53253122-444227D2-0A5B-4DEB-919E-EFB17A7987BEQ57982384-D5BE83A0-773B-4FD5-8ABC-4EBA8E48944D
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Treatment of chronic hepatitis C in southern Taiwan.
@ast
Treatment of chronic hepatitis C in southern Taiwan.
@en
type
label
Treatment of chronic hepatitis C in southern Taiwan.
@ast
Treatment of chronic hepatitis C in southern Taiwan.
@en
prefLabel
Treatment of chronic hepatitis C in southern Taiwan.
@ast
Treatment of chronic hepatitis C in southern Taiwan.
@en
P2093
P2860
P356
P1433
P1476
Treatment of chronic hepatitis C in southern Taiwan.
@en
P2093
Chia-Yen Dai
Ming-Lung Yu
Wang-Long Chuang
Wen-Yu Chang
P2860
P304
P356
10.1159/000087271
P577
2006-01-01T00:00:00Z